Embed Size (px)
Citation preview
Corporate Presentation
December 2017
Conquering Upper Limb Paralysis with Wearable Medical Robotics
Legal Disclaimer
This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the
Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business,
and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the
Company’s management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and
statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with
any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements
contain these identifying words. Forward-looking statements, which are included in accordance with the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties
and other factors. These risks and uncertainties include, among others, risks related to the Company’s liquidity and financial position, the
trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information
about factors that potentially could affect Myomo's business and financial results are included in Myomo's Form S-1 Registration Statement
filed with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated
events.
2
Why Myomo?
Moving from Controlled Introduction to Scale Up
Large Unmet Need in the US and Worldwide for Upper Limb Paralysis
Only Commercially Available Upper Limb Medical Device
Growing Body of Clinical Evidence; Reduces Cost of Care
Largest Home User Base in Wearable Robotics Market
Strong IP Portfolio of MIT and Company Patents
Current Reimbursement and Path to HCPCS Code
Attractive Gross Margins of 65%
Proven Management Team and Advisors
3
Significant Unmet Need: 3 Million Cases in U.S.
One of Every 100 People You Know Has at Least Some Form of Upper Limb Paralysis*
4 *Source: Christopher and Dana Reeve Foundation Survey and Myomo Estimates
Boston CBS TV Affiliate News: 11/13/17
5
Myoelectric Orthotics: Restore Function, Real World Benefits
1. User’s Brain is the Controller
2. Sensors Detect
Muscle Signal
3. Surface EMG
Signal Processing
4. MyoPro® Powered Arm Brace
Assists with Movement
Neuroscience & Robotics Technology for Cost-effective Treatment of Upper Limb Paralysis
6
Large Market Opportunity*
CAUSES OF
UPPER EXTREMITY
PARALYSIS
STROKE BRACHIAL
PLEXUS INJURY SPINAL CORD
INJURY
MULTIPLE
SCLEROSIS
TRAUMATIC
BRAIN INJURY
ALS
(Assumes average selling price of $13.4k per device)
25% of 3M existing cases of upper extremity paralysis $10 B Total US Market Size
25% of 350k new cases each year $1.2 B New Incidences / Year +
US + EU + ROW $30 B Estimate Includes:
Total US Market Potential
Total Worldwide Market Potential
7
*Source: Christopher and Dana Reeve Foundation Survey,
National Stroke Association, World Health Organization, and
Myomo Estimates
Capital Efficient, Outsourced ISO Certified Manufacturing &
Established O&P Distribution Channels
8
Robotic
Components (MA) • Electronics
• Elbow Motor Unit
• Hand Actuator Unit
• Sensors
• UDI Labeling
Custom
Fabrication (OH) • Custom Orthotic
Components
• Soft Goods
• Harness
• Final Assembly and QA
Direct Sales
3,000 O&P Clinics
Distribution Mfg.
MyoPro
Centers of Excellence
Veterans
Private Payers,
Workers Comp
Competitive Landscape of O&P and Robotics
Lower
Limb
Products
Upper
Limb
Products
Lower
Limb
Products
Upper
Limb
Products
Foot Drop Exoskeletons
9
Only Commercially Available Upper Limb Product Line to Restore Function
Unit Volume
Orthotics Prosthetics
Stance Control
Supported by Growing Body of Clinical Evidence
Randomized Control
Study of MyoPro Use
By Stroke Patients
Clinical Outcomes For
Brachial Plexus Injury
Patients
Study of MyoPro Use
For Traumatic Brain
Injury
Functional Benefits of
MyoPro Orthosis
Safety & Efficacy Study Home User Study
10
US Reimbursement: Strategy for Broad Coverage
Hundreds of Devices Have Been Reimbursed to Date
DME Misc. Code: L3999
Reimbursement ranges from $20,000 to $50,000 based on MyoPro model
MyoPro Device Price to Channel = $10,000 to $25,000
VA, Private Payers, Worker’s Comp
Case-by-Case Coverage & Appeals
Next Steps: HCPCS Code, Coverage Policies
11
Moving from Controlled Introduction to Scale Up
12
R&D
Phase I
Controlled
Introduction
Phase II
Commercial
Scale Up
Phase III
Broader
Adoption
Phase IV
Standard of
Care
Phase V
2006 2012 2017 2019E 2021E
Positioned to Achieve Value Inflection Points with Growth Funds Secured
Increased Sales & Marketing
MyoPro Centers of Excellence
Business Drivers: Scaling Up Revenue
13
Sales &
Marketing
Product
Development
Clinical Studies &
Reimbursement
International
Expansion
Recent Full-Time Hires
Chief Medical Officer
Dr. Brandon Green
Chief Marketing Officer
Cliff Conneighton
National Business
Development Mgr.
Lorraine Hale
14
Inbound MyoPro Inquiries & Requests
From Patients and Clinicians…
15
Dr. David (NY)
“My patient has suffered major stroke but excelled outpatient
rehab, MyoPro would return functionality to his right arm!”
“My brother-in-law is a stroke victim with no movement in
his arm in the last two years. He is able to walk with a
brace and cane”
Steve (WA)
“Stroke. Left Side Weakness”
Marvin (Veteran)
“Brachial Plexus Injury from Birth”
Rita (TX)
Growing Roster of MyoPro Centers of Excellence
16
New Locations Added to 31 in the U.S. Now Certified
Business Drivers: Scaling Up Revenue
17
MyoPro 2
Pediatric Device
Sales &
Marketing
Product
Development
Clinical Studies &
Reimbursement
International
Expansion
Increased Sales & Marketing
MyoPro Centers of Excellence
Pipeline Progress Update: Pediatric
18
Fit First Adolescent Patient with Existing Device @ Easter Seals
Pediatric Prototype for Younger Children
Business Drivers: Scaling Up Revenue
19
Demonstrated Outcomes and
CMS Application
Germany, Canada
Sales &
Marketing
Product
Development
Clinical Studies &
Reimbursement
International
Expansion
MyoPro 2
Pediatric Device
Increased Sales & Marketing
MyoPro Centers of Excellence
First Patient Fit In Germany; Ottobock Launch Underway
Sales & Clinical Support Team Training in Progress
20
Market Entry into Canada Approved
21
Business Drivers: Scaling Up Revenue
22
Sales &
Marketing
Product
Development
Clinical Studies &
Reimbursement
International
Expansion
Demonstrated Outcomes and
CMS Application
Germany, Canada
MyoPro 2
Pediatric Device
Increased Sales & Marketing
MyoPro Centers of Excellence
Revenue Growth 2016-17
23
0
100
200
300
400
500
600
1Q 2Q 3Q
Rev
en
ue (
$000)
2016 2017
June 2017 IPO
+165% YoY
+59% QoQ
Balance Sheet Highlights
24
As of
Sept. 30,
2017
Secondary
Offering & Note
Payoff
Proforma
As of Sept. 30,
2017
Cash $5.0M $9.1M $14.1M
Debt:
Notes Payable & Accrued
Interest(1)
$1.1M $(1.1)M $ -
Notes Payable, MLSC(2) $1.0M $1.0M
Total Debt $2.1M $(1.1)M $1.0M
(1) On November 13, 2017, the Company repaid Lender all outstanding principal and accrued but unpaid interest under the Notes, constituting approximately $1.1M
in cash by issuing 193,509 shares of the Company’s Common Stock.
(2) To be paid in December 2017.
Capital Structure
25
Traded on NYSE American: MYO
Shares outstanding as of 12.1.17: 10.5 million,
(17.1 million fully diluted) (1)
Debt as of 12.31.17: None
Analyst Coverage: HC Wainwright, See Thru Equity
(1) Amounts do not include underwriter option to purchase 626,250
shares of common stock
Proven Technology & Healthcare Leadership
Executive Management Board of Directors & Advisors
Paul R. Gudonis | Chairman & CEO Robotics, Software, HBS MBA, BSEE
Ross D. Zafonte, DO | Chair, Scientific Advisory Board
Harvard Medical School, Spaulding Rehabilitation Hospital
Gene Tacy, MSEE | VP of Engineering Intel, GE Corporate R&D, NComm Inc.
Thomas Kirk | Lead Independent Director Former CEO, Hanger Clinics
Past President, AOPA Industry Association
Brandon Green, DO, CP | CMO Medical Director of United Prosthetics
Amy Knapp | Board Member Former Senior Executive, United Healthcare
Davie Mendelsohn, RN | VP Sales Ossur, Ottobock, Touch Bionics
Steve Sanghi | Board Member CEO, Microchip Technology Inc.
Thomas Crowley | Board Member Experienced Med Device CEO
26 Ralph Goldwasser, CPA | CFO BBN Inc., Avici Systems, Unica Corp.
Jonathan Naft CPO, VP | GM O&P Industry Leader, BME
Why Myomo?
Moving from Controlled Introduction to Scale Up
Large Unmet Need in the US and Worldwide for Upper Limb Paralysis
Only Commercially Available Upper Limb Medical Device
Growing Body of Clinical Evidence; Reduces Cost of Care
Largest Home User Base in Wearable Robotics Market
Strong IP Portfolio of MIT and Company Patents
Current Reimbursement and Path to HCPCS Code
Attractive Gross Margins of 65%
Proven Management Team and Advisors
27
Paul R. Gudonis
Chairman & CEO [email protected]
(617) 861-4191
28
Conquering Upper Limb Paralysis with Wearable Medical Robotics
